Spectral Md Share Discussion Threads

[idomeneo] 22/8/2023 08:48

WH Island note: "The proposed merger EV also stands at a discount to our sum-of-the-parts fair valuation of SMD of 157p per share"

[hatfullofsky] 11/8/2023 22:33

Why, to quote Mr T - you crazy fool

[blackhorse23] 11/8/2023 11:53

Switched to CURY

[rimau1] 11/8/2023 07:18

I suppose the additional risk is (1) the deal not happening (although it feels very advanced now, still requires shareholder sign off on or around 18 Aug), and (2) the risk that the share price falls on re-listing

[heidthebawagain] 10/8/2023 20:27

I discovered Spectral after listing to a chat on Vox Markets today and after having a dig about bought 10k shares at just under 50p. I'm prepared to buy a lot more if the share starts getting some momentum up the way. Any idea why the arbitrage opportunity is so large? Am I missing something (aside from the move to Nasdaq which may prevent some investors from holding it)?

[rimau1] 10/8/2023 10:47

8th september for the delisting on AIM and listing on Nasdaq. SMD shareholders will own £17m ordinary shares in the new company at $10.17 a share. Obviously the stock could tank on relisting and it might be a few days before broking accounts are updated to trade the new shares but there is a theoretical paper profit of 100% at todays prices.

[rimau1] 01/8/2023 08:35

New presentation released which provides a good investment case, clear why Rosecliff are willing to pay a premium to snare SMD.

[idomeneo] 28/7/2023 08:53

Investment case: This is an arbitrage play - the SPAC in the US is worth 101p. If the deal goes through then the company gets subsumed into the SPAC and you double your money. The company is funded by the US quango-style federal body. The product produced by the company enables burn wound triage in the case of mass casualty. The next big event from Barta could be for it to buy the machines which would come to $500m. The share swap to the SPAC is due in Q3. However, the word SPAC should send warning signals as well as the UK vendor - if an entity wanted to buy SMD why don't they just use the cash they have raised for the SPAC.

[rimau1] 18/4/2023 08:23

Anyone else holding these or just me? The federal R&D win is excellent news, $4m is a big additional chunk.

[barbello] 07/7/2022 10:21

Interesting to see the waiver announced today that allows largest shareholder to buy more without triggering a bid. In so little volume even a small amount of buying might help the shares. I'm itself it doesn't change the value but if the people closest to the business think the shares are cheap that is encouraging

[barbello] 16/11/2021 15:04

All very sensible points. Stifel appointment as joint broker hopefully provides some ballast.

[t0pgrader] 16/11/2021 09:58

Interesting company.

A few red flags for me:

1. The Nomad is the spivvy house of share price Angel

2. 43.5m outstanding share options ie 32% of the issued share cap is massively dilutive. Plus the Admission doc says "a further 4,844,118 share options remain to be granted under the existing incentive plans."

3. 80% of company in non-public hands so exiting is likely to be difficult

4. Further dilution from the "Spangenberg Options" - Spangenberg has the right to buy 2m shares at an average of 20c each

5. The Company is not subject to the City Code because its registered office and its place of central
management and control are outside the UK. This becomes more of an issue when mixed with the spivvery of share price Angel.

[barbello] 16/11/2021 09:40

So bought 15k at 36.4

[barbello] 16/11/2021 09:39

Mkt Cap now below £50m after share price slump yet strong trial result and they have had $93m of non-dilutive grants as per..."Spectral MD has to date received substantial support from the U.S. government with contracts from institutions such as Biomedical Advanced Research and Development Authority, National Science Foundation, National Institute of Health and Defense Health Agency in support of the burn application for its DeepView® solution, with total grant funding received to date from all of these organizations of over $93 million, including $40.5 million received in 2021. This grant funding is non-dilutive to our shareholders and the Company believes it validates the important nature of our mission and technology. The Company leverages this funding to support R&D efforts that are applicable to burn, DFU and potentially other indications where DeepView can play an important role in Day 1 wound healing assessment.

[barbello] 16/11/2021 09:01

Brighter people than me said fall since listing was bonkers, but that Patience required...which is fine

[barbello] 16/11/2021 08:59

Sort of...dipped toe a couple of weeks ago at 36

[t0pgrader] 16/11/2021 07:38

Anyone here?

[rambutan2] 23/6/2021 05:13

Conclusiona from the Experts Report pgs70-91, which is very well worth a read:

7. Conclusions
Development and commercialisation of new medical devices in healthcare is a high-risk activity but when executed successfully can deliver significant rewards. For SMD to achieve its potential as a provider of medical devices in the wound healing sector, assuming that the DFU and burns clinical trials are successful, its commercial success will rely to a greater degree on adoption and penetration into US and EU markets. This will require significant sales and marketing efforts in penetrating clinical networks in both territories as well as successfully navigating the various regulatory and payer communities. The Company is cognisant of these requirements and appears to have appropriate plans to address these, some of which have already been or are being implemented.

Many of the technical and development risks appear to have been addressed through the evolution of the system through 1st and 2nd generation systems. Final proving of the 3rd generation system’s capabilities has yet to be completed which is the purpose of the ongoing and planned clinical trials. If the system performs as expected in those trials, there appear to be few if any competing systems in the market or late-stage development that can provide the same analytical and predictive capabilities of the Deepview® device. Whilst this does not guarantee commercial success, it would mean that the device would likely be regarded best in class in a clinical setting with limited diagnostic capability.

The future development plans and commercialisation of its technology in different markets will likely mean that SMD will require further funding beyond that provided under the BARDA agreement and any funds from a successful new issue on AIM. Whilst there is no guarantee that such future funding will materialise, good clinical data from the ongoing and planned clinical trials will position it well for regulatory and commercial success.

[rambutan2] 23/6/2021 04:05

From the admission doc pg27:

3.7 Market and Competition
To the Group’s knowledge, a predictive wound healing diagnostic imaging technology is not available to clinicians who treat wounds. DeepView®’s competitive advantage is that it is the only AI-enabled wound imaging technology that translates raw physiological data/images into an output that is directly correlated to wound healing.

Several companies have developed wound imaging systems for burn injuries and DFUs however these systems incorporate technology such as spatial frequency domain imaging, thermal imaging, photographic documentation, hyperspectral imaging, and near-infrared imaging that provide physiologic data to the physician. Ultimately, this physiologic data only provides an indirect linkage to wound healing and does not display a binary result of “healing vs. non-healing”. Furthermore, the majority of systems in the wound care space are merely documentation tools that record measurements of the wound for health record purposes and still rely upon subjective clinician opinion for treatment decisions. The advent of a novel technology such as DeepView® not only has the potential to disrupt the therapeutic pathway within the wound care market, but also creates a new diagnostic market for wound care that did not exist previously for clinics and physicians.

A summary of some of the existing wound imaging technologies for burn injuries and DFUs are set out below, further details of which are included in the Expert’s Report in Part III of this document.

Parable Health, Inc: Provides a wound care software solution involving digital wound documentation, collaboration and management for mobile devices and tablets. The Parable Health system does not have regulatory approvals as a medical device and whilst it may simplify diagnostic and monitoring procedures, it appears to still rely upon the subjective clinician opinion.

HyperMed Imaging, Inc: Has developed a handheld diagnostic imaging device that is used to assess tissue oxygenation. The technology has FDA 510(k) clearance and CE-mark approvals however it does not appear to have the same level of sophistication or diagnostic capability as DeepView®.

Perceptive Solutions, Inc: Provides a 3D wound imaging software solution for improved electronic medical records, however does not appear to have any diagnostic capability to inform clinical decisions.

Hitachi Healthcare Americas Corporation: Has developed Noblus Wound Care Wound- Mapping® Ultrasound Assessment for DFU. The system can provide information regarding tissue thickness, blood flow and bone invasion (osteomyelitis). These can assist clinicians in decision making but do not appear to be as sophisticated as DeepView® and still require subjective triage by the clinician for treatment.

Tissue Analytics, Inc: Provides a mobile phone or tablet imaging application that generates a 3D image of a wound for accurate measurement and tracking of healing, however it does not appear to provide any predictive capability for wound healing or treatment triage.

Healthy.io Ltd: Uses smartphones as a medical device. It has CE marking and FDA registration and is generating standardised digital records of wound progression to track wound healing over time and assist in better clinical decision making. It does not appear to have predictive capability for wound healing.

[rambutan2] 22/6/2021 15:19

Admission to trading on AIM

& First Day of Dealings

LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd., a predictive analytics group that develops proprietary AI algorithms and optical technology for faster treatment decisions in wound care, is pleased to announce the admission of its entire issued share capital, being 136,077,064 shares of common stock, to trading on AIM ("Admission") will take place and dealings will commence at 8.00 a.m. today under the ticker 'SMD' and ISIN 'USU8457V1099'.

The Company's Admission Document was published on 16 June 2021 and is available here:

Summary and Highlights:

-- Oversubscribed Placing for gross proceeds of GBP11.3 million (c.US$16 million)
-- The Placing was conducted at a pre-IPO fully diluted valuation of GBP95m
-- Placing price per share of common stock of 59 pence
-- Market capitalisation (at the Placing Price) of approximately GBP80 million on Admission
-- The 19,067,797 shares of New Common Stock being placed represent c. 14 per cent. of the Enlarged Share Capital

[rambutan2] 22/6/2021 15:17

The Group is developing the only AI enabled predictive wound healing diagnostic imaging technology that translates raw physiological data/images into an output providing ‘Day One’ healing assessments for wound care. Through its strategic partnerships with multiple clinical and academic partners, Spectral is able to access large, diverse and specific sets of wound data inputs to develop, validate and improve its DeepView® algorithms efficiently and effectively. The Group believes it has the pre-eminent proprietary clinical wound database. The depth and quality of Spectral’s proprietary data is critical to develop a leading wound assessment technology with demonstrated clinical need across burn, DFU and other indications with a positive impact on health economics and patient outcomes, while safeguarding patient data and privacy.

DeepView® is a portable imaging platform that allows for immediate wound healing assessment and provides clinicians with physiological information that is not visible to the human eye.

[stu31] 11/2/2021 16:30

Strategic Metals Ltd. Vends 3 Yukon Silver Projects

Vancouver, BC – February 11, 2021 – Strategic Metals Ltd. (TSX-V:SMD) ("Strategic" or "the Company") is pleased to announce that it has signed a binding letter of intent (the "LOI") with Honey Badger Silver Inc. (TSX-V:TUF) ("Honey Badger") to vend three of its silver-focused Yukon Properties: Groundhog, Hy, and Plata.

"Strategic is happy to be working with Chad Williams and the Honey Badger team," states Strategic CEO Doug Eaton. "Honey Badger's financial and technical strengths significantly increase Strategic shareholders' leverage to the current bull market in silver."

The Properties

Plata property - lies within the Tintina Gold Belt and displays a number of similarities to the Keno Hill Silver Camp located about 180 km west. A reported 2,041 tonnes of hand sorted material was shipped from high grade veins on the Plata property to a smelter, yielding about 9,020 kg (290,000 ounces) of silver; this equates to a recovered silver grade of approximately 4,420 grams per tonne (g/t) silver.

Groundhog property - Silver mineralization was first discovered in the Groundhog area in 1956. Historical exploration programs on the road accessible property have yielded rock samples that returned assays of up to 13,028 g/t silver, 85% lead, 4.46% zinc and 3.73% copper, but did not evaluate the gold potential of the project. Given Groundhog falls within a belt of high-grade gold occurrences, including the former Ketza Mine, located 30 km to the east, in 2019 a Strategic completed a prospecting program which discovered oxidized breccia that assayed 5.91 g/t gold.

Hy property - The road accessible Hy property covers many silver occurrences that were first discovered on the property in 1964. Trench results include 370.3 g/t silver, 14.01% zinc and 8.22% lead over 3.20 m at the Miko Zone and 684 g/t silver, 9.30% zinc and 11.01% lead at the Dusty Zone.

LOI Terms

In consideration for a 100% interest in the Properties, Honey Badger has agreed to issue to Strategic common shares in the capital of Honey Badger equal to 19.9% of the issued and outstanding common shares following a $3 million equity financing and grant to Strategic the right to participate in the next three equity financings undertaken by the Company after the transaction's closing on or before April 30, 2021 or on such other date as may be mutually agreed to by the parties. Strategic will retain a 2% net smelter royalty on minerals other than silver. A Definitive Agreement is anticipated prior to March 12, 2021.

Technical information in this news release has been approved by Heather Burrell, P.Geo., a geologist with Archer, Cathro & Associates (1981) Limited and qualified person for the purpose of National Instrument 43-101.

About Strategic Metals Ltd.

Strategic is a project generator with a portfolio of more than 130 projects that are the product of over 50 years of focussed exploration and research by a team with a track record of major discoveries. Current projects include more than 80 properties where precious metals are a major component. Projects available for option, joint venture or sale include drill-confirmed prospects and drill-ready targets with high-grade surface showings and/or geochemical anomalies and geophysical features that resemble those at nearby deposits.

Strategic has a current cash position of over $9 million and large shareholdings in a number of active mineral exploration companies including 38.9% of GGL Resources Corp., 33.5% of Rockhaven Resources Ltd., 19.2% of Precipitate Gold Corp. and 18.7% of Silver Range Resources Ltd. All of these companies are well funded and are engaged in promising exploration projects. Strategic also owns 21.9% of Terra CO2 Technologies Holdings Inc., a private Delaware corporation which recently completed a US$9.2 million financing to advance its environmentally-friendly, cost-effective alternative to Portland cement. The current value of Strategic's stock portfolio is approximately $33 million.

[stu31] 03/12/2020 02:01

Strategic Metals Ltd. Announces New Normal Course Issuer Bid to Succeed the Normal Course Issuer Bid Which Will Expire on December 2, 2020

Vancouver, BC - November 30, 2020 – Strategic Metals Ltd. (TSX-V: SMD) (“Strategic221;) announces that it is making a new Normal Course Issuer Bid (the “New Bid”) pursuant to the provisions of TSX Venture Exchange Policy 5.6, to succeed its existing Normal Course Issuer Bid (the “Old Bid”), as accepted by the TSX Venture Exchange on November 28, 2019.

Strategic has purchased no shares under the Old Bid, which will expire on December 2, 2020. The New Bid will consist of the acquisition by Strategic of up to 8,700,000 common shares of its capital stock, representing approximately 10% of the “public float” of 87,599,346 common shares upon the date of commencement of the New Bid. (There are currently 106,705,767 common shares of Strategic issued and outstanding.) The New Bid will commence on December 3, 2020, and will expire on December 2, 2021.

Strategic is making the New Bid, to succeed the Old Bid (which was limited to an aggregate of 6,600,000 common shares), because it is of the opinion that fluctuating global market conditions periodically (and currently) may result in unwarranted reductions in Strategic’s share price that do not reflect the underlying value of its assets. Strategic will utilize unallocated cash resources to effect purchases under the New Bid with a view to capitalizing on these potential price weaknesses. Shares purchased under the New Bid will be made at Management’s discretion based on market conditions, and will be returned to Strategic’s treasury for cancellation.